-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective Nintedanib, an intracellular inhibitor of tyrosine kinase, has been approved by the.
Food and Drug Administration to slow the decline in lung function in patients with systemic sclerosis-associated interstitial lung disease ( ILD .
Methods : The INBUILD trial enrolled patients with non-idiopathic pulmonary fibrosis with fibrotic ILD , diffuse fibrotic lung disease >10% on high-resolution computed tomography , forced vital capacity percent predicted (FVC%) ≥45 % , and lung Carbon monoxide percent predicted ≥ 30% to < 80.
RESULTS : Among 170 patients with autoimmune disease-related ILD , the rate of decline in FVC at 52 weeks was -79 ml/ year in the nintedanib group and -176 ml/ year in the placebo group (difference 107 ml/ year [95%] Confidence interval 22, 182]; nominal P=012.
CONCLUSIONS : In the INBUILD trial, nintedanib slowed the rate of decline in FVC in patients with progressive fibrotic autoimmune disease-associated ILD , with adverse events manageable in most patient.
Source: Matteson, EL, Kelly,.
